BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18704420)

  • 1. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
    Alasfoor K; Alrasheed M; Alsayegh F; Mousa SA
    Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
    Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
    Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.
    Pamuk GE; Pamuk ON; Başlar Z; Ongören S; Soysal T; Ferhanoğlu B; Aydin Y; Ulkü B; Aktuğlu G; Akman N
    Ann Hematol; 2002 Aug; 81(8):436-40. PubMed ID: 12224000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.
    Parodi E; Rivetti E; Amendola G; Bisogno G; Calabrese R; Farruggia P; Giordano P; Matarese SM; Nardi M; Nobili B; Notarangelo LD; Russo G; Vimercati C; Zecca M; De Mattia D; Ramenghi U
    Br J Haematol; 2009 Feb; 144(4):552-8. PubMed ID: 19036077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
    Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
    Riksen NP; Keuning JJ; Vreugdenhil G
    Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
    Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
    Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
    Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M;
    Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases.
    Li HQ; Zhang L; Zhao H; Ji LX; Yang RC
    Chin Med J (Engl); 2005 Jan; 118(1):34-7. PubMed ID: 15642223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
    Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.